Achmea Investment Management B.V. Has $1.39 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Achmea Investment Management B.V. lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 63.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,905 shares of the medical device company's stock after selling 31,074 shares during the quarter. Achmea Investment Management B.V.'s holdings in DexCom were worth $1,393,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock worth $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after buying an additional 710,858 shares in the last quarter. Groupama Asset Managment lifted its holdings in shares of DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after buying an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after buying an additional 876,739 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Remove Ads

DexCom Trading Up 3.8 %

Shares of DexCom stock traded up $2.68 during midday trading on Wednesday, reaching $73.38. The company had a trading volume of 4,302,371 shares, compared to its average volume of 3,887,224. The stock has a fifty day moving average price of $83.64 and a 200 day moving average price of $76.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $28.67 billion, a PE ratio of 51.31, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company's stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 104,657 shares of company stock valued at $8,019,422. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and boosted their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Finally, Canaccord Genuity Group lifted their target price on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.